FDA approves perioperative pembrolizumab for head and neck cancer — the first approval for this cancer in 6 years
Evidence stage: High-Certainty EvidenceRegulatory status: FDA Approved
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed